Inovio Pharmaceuticals Inc

Find Ratings Reports
INO : NASDAQ : Health Care
$9.17 -0.28 | -3.00%
Today's Range: 9.09 - 9.48
Avg. Daily Volume: 1,509,400
08/31/16 - 3:59 PM ET

Financial Analysis


INOVIO PHARMACEUTICALS INC's gross profit margin for the second quarter of its fiscal year 2016 has significantly increased when compared to the same period a year ago. Even though sales increased, the net income has decreased, representing a decrease to the bottom line. INOVIO PHARMACEUTICALS INC is extremely liquid. Currently, the Quick Ratio is 4.08 which clearly shows the ability to cover any short-term cash needs. The company's liquidity has decreased from the same period last year, indicating deteriorating cash flow.

During the same period, stockholders' equity ("net worth") has decreased by 10.28% from the same quarter last year. Overall, the key liquidity measurements indicate that the company is very unlikely to face financial difficulties in the near future.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12-months. To learn more visit www.TheStreetRatings.com.



Income Statement Q2 FY16 Q2 FY15
Net Sales ($mil)6.25.29
EBITDA ($mil)-18.44-15.66
EBIT ($mil)-19.23-16.12
Net Income ($mil)-18.71-6.25


Balance Sheet Q2 FY16 Q2 FY15
Cash & Equiv. ($mil)134.53154.59
Total Assets ($mil)203.99201.7
Total Debt ($mil)0.00.0
Equity ($mil)161.99180.56


Profitability Q2 FY16 Q2 FY15
Gross Profit Margin-297.23-296.31
EBITDA Margin-297.22-296.31
Operating Margin-309.9-304.96
Sales Turnover0.220.07
Return on Assets-19.17-15.57
Return on Equity-24.14-17.4
Debt Q2 FY16 Q2 FY15
Current Ratio4.1711.17
Debt/Capital0.00.0
Interest Expense0.00.0
Interest Coverage0.00.0


Share Data Q2 FY16 Q2 FY15
Shares outstanding (mil)73.4871.81
Div / share0.00.0
EPS-0.26-0.09
Book value / share2.22.51
Institutional Own % n/a n/a
Avg Daily Volume1521175.01734232.0

Valuation


SELL. The current P/E ratio is negative, which has no meaningful value in the assessment of premium or discount valuation, it simply displays that the company has negative earnings. Conducting a second comparison, its price-to-book ratio of 3.93 indicates a premium versus the S&P 500 average of 2.82 and a significant discount versus the industry average of 10.35. The price-to-sales ratio is well above the S&P 500 average, but well below the industry average. After reviewing these and other key valuation criteria, INOVIO PHARMACEUTICALS INC proves to trade at a discount to investment alternatives within the industry.


Price/Earnings
1 2 3 4 5
premium   discount
  Price/Cash Flow
1 2 3 4 5
premium   discount
INO NM Peers 42.54   INO NM Peers 20.68

Neutral. The absence of a valid P/E ratio happens when a stock can not be valued on the basis of a negative stream of earnings.

INO's P/E is negative making this valuation measure meaningless.

 

Neutral. The P/CF ratio, a stock’s price divided by the company's cash flow from operations, is useful for comparing companies with different capital requirements or financing structures.

INO's P/CF is negative making the measure meaningless.

 
Price/Projected
Earnings
1 2 3 4 5
premium   discount
  Price to
Earnings/Growth
1 2 3 4 5
premium   discount
INO NM Peers 30.92   INO NA Peers 0.48

Neutral. The absence of a valid price-to-projected earnings ratio happens when a stock can not be valued on the basis of a negative expected future earnings.

INO's ratio is negative making this valuation measure meaningless.

 

Neutral. The PEG ratio is the stock’s P/E divided by the consensus estimate of long-term earnings growth. Faster growth can justify higher price multiples.

Ratio not available.

 
Price/Book
1 2 3 4 5
premium   discount
  Earnings Growth
1 2 3 4 5
lower   higher
INO 3.93 Peers 10.35   INO -7.84 Peers 0.01

Discount. A lower price-to-book ratio makes a stock more attractive to investors seeking stocks with lower market values per dollar of equity on the balance sheet.

INO is trading at a significant discount to its peers.

 

Lower. Elevated earnings growth rates can lead to capital appreciation and justify higher price-to-earnings ratios.

However, INO is expected to significantly trail its peers on the basis of its earnings growth rate.

 
Price/Sales
1 2 3 4 5
premium   discount
  Sales Growth
1 2 3 4 5
premium   discount
INO 14.34 Peers 539.66   INO 201.24 Peers 52.09

Discount. In the absence of P/E and P/B multiples, the price-to-sales ratio can display the value investors are placing on each dollar of sales.

INO is trading at a significant discount to its industry on this measurement.

 

Higher. A sales growth rate that exceeds the industry implies that a company is gaining market share.

INO has a sales growth rate that significantly exceeds its peers.

 

 

Latest Stock Upgrades/Downgrades